Leerink Partners Maintains AdaptHealth at Outperform and Raises Price Target
Leerink Partners has maintained its 'Outperform' rating on AdaptHealth Corp. while increasing the price target from $7 to $8.
Stocks · News reference
UBS Adjusts Price Target on AdaptHealth
UBS lowered its price target on AdaptHealth shares from $10 to $9 while maintaining a Buy rating.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AdaptHealth's Capitated Contract Margins Improve, RBC Says
RBC Capital Markets reported an improvement in AdaptHealth's capitated contract margins.
AdaptHealth Corp. Reports Third Quarter 2026 Financial Results
AdaptHealth Corp. announced its financial results for the third quarter ended September 30, 2026, reporting revenue of $745.6 million and a net loss of $168.2 million.
8-K filing — AdaptHealth Corp. (AHCO)
Filed: 2026-11-03 AccNo: 0001628280-26-069116 Size: 452 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
AdaptHealth Corp. Announces Third Quarter 2026 Earnings Release Date
AdaptHealth Corp. has scheduled the release of its financial results for the third quarter of 2026.
Baird Maintains Outperform on AdaptHealth, Lowers Price Target to $9
Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $10 to $9.